Induction of innate and adaptive immune responses after stopping NA therapy in HBeAg negative chronic hepatitis B
F Rinker, C Höner zu Siederdissen, CM Bremer, B Bremer, CS Falk, MP Manns, H Wedemeyer, D Glebe, ARM Kraft, M Cornberg · Zeitschrift für Gastroenterologie · 2015 · Heft 12
Bibliografische Angaben
Zusammenfassung
Stopping nucleos(t)ide analogue (NA) treatment before HBsAg loss is currently debated as a concept to induce HBsAg decline. In a prospective single center study we show that stopping NA treatment in HBeAg-negative patients is safe and leads to a significant decline of HBsAg. To understand mechanisms leading to HBsAg decline, the three HBV surface proteins (S-, L and MHBs), core-related antigen (HBcrAg), cytokine/chemokine levels and HBV-specific T cell responses were measured before and after stop of NA therapy. In 13/15 patients a virological relapse with HBV-DNA and ALT flairs at week 4 (n = 4), 8 (n = 11), 24…
